Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00963820 · OUTCOME

Accumulation Ratio: Day 15 AUC0-168 / Day 1 AUC0-168 for MLN2238

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma · Source last updated 2018-01-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
unitless
Interval / dispersion
Standard Deviation
Time frame
Day 15 of Cycle 1

What was measured

MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).

Analysis population: Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of accumulation ratio.

Groups in this outcome

0.24 mg/m^2

Ixazomib citrate, 0.24 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

0.48 mg/m^2

Ixazomib citrate, 0.48 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

0.80 mg/m^2

Ixazomib citrate, 0.80 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

1.20 mg/m^2

Ixazomib citrate, 1.20 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

1.68 mg/m^2

Ixazomib citrate, 1.68 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

2.23 mg/m^2

Ixazomib citrate, 2.23 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

2.97 mg/m^2

Ixazomib citrate, 2.97 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

3.95 mg/m^2

Ixazomib citrate, 3.95 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

Relapsed and Refractory (RR)

Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m\^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

VELCADE-relapsed (VR)

Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m\^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

PI naïve

Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

Carfilzomib

Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
0.24 mg/m^20
0.48 mg/m^20
0.80 mg/m^20
1.20 mg/m^20
1.68 mg/m^22
2.23 mg/m^21
2.97 mg/m^21
3.95 mg/m^21
Relapsed and Refractory (RR)1
VELCADE-relapsed (VR)3
PI naïve2
Carfilzomib2

Reported measurements

Source class 1
Values in unitless · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.68 mg/m^22.640.3960Not reportedNot reportedNot reported
2.23 mg/m^21.45NANot reportedNot reportedCan not be calculated for 1 participant.
2.97 mg/m^22.25NANot reportedNot reportedCan not be calculated for 1 participant.
3.95 mg/m^21.19NANot reportedNot reportedCan not be calculated for 1 participant.
Relapsed and Refractory (RR)2.25NANot reportedNot reportedCan not be calculated for 1 participant.
VELCADE-relapsed (VR)2.190.8228Not reportedNot reportedNot reported
PI naïve1.970.5869Not reportedNot reportedNot reported
Carfilzomib2.370.2192Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG004
        spread
        0.3960
        value
        2.64
      2. comment
        Can not be calculated for 1 participant.
        group Id
        OG005
        spread
        NA
        value
        1.45
      3. comment
        Can not be calculated for 1 participant.
        group Id
        OG006
        spread
        NA
        value
        2.25
      4. comment
        Can not be calculated for 1 participant.
        group Id
        OG007
        spread
        NA
        value
        1.19
      5. comment
        Can not be calculated for 1 participant.
        group Id
        OG008
        spread
        NA
        value
        2.25
      6. group Id
        OG009
        spread
        0.8228
        value
        2.19
      7. group Id
        OG010
        spread
        0.5869
        value
        1.97
      8. group Id
        OG011
        spread
        0.2192
        value
        2.37
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    4. group Id
      OG003
      value
      0
    5. group Id
      OG004
      value
      2
    6. group Id
      OG005
      value
      1
    7. group Id
      OG006
      value
      1
    8. group Id
      OG007
      value
      1
    9. group Id
      OG008
      value
      1
    10. group Id
      OG009
      value
      3
    11. group Id
      OG010
      value
      2
    12. group Id
      OG011
      value
      2
    units
    Participants
description
MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).
dispersion Type
Standard Deviation
groups
  1. description
    Ixazomib citrate, 0.24 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG000
    title
    0.24 mg/m^2
  2. description
    Ixazomib citrate, 0.48 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG001
    title
    0.48 mg/m^2
  3. description
    Ixazomib citrate, 0.80 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG002
    title
    0.80 mg/m^2
  4. description
    Ixazomib citrate, 1.20 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG003
    title
    1.20 mg/m^2
  5. description
    Ixazomib citrate, 1.68 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG004
    title
    1.68 mg/m^2
  6. description
    Ixazomib citrate, 2.23 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG005
    title
    2.23 mg/m^2
  7. description
    Ixazomib citrate, 2.97 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG006
    title
    2.97 mg/m^2
  8. description
    Ixazomib citrate, 3.95 mg/m\^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG007
    title
    3.95 mg/m^2
  9. description
    Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m\^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG008
    title
    Relapsed and Refractory (RR)
  10. description
    Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m\^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG009
    title
    VELCADE-relapsed (VR)
  11. description
    Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG010
    title
    PI naïve
  12. description
    Ixazomib citrate, 2.97 mg/m\^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
    id
    OG011
    title
    Carfilzomib
param Type
MEAN
population Description
Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of accumulation ratio.
reporting Status
POSTED
time Frame
Day 15 of Cycle 1
title
Accumulation Ratio: Day 15 AUC0-168 / Day 1 AUC0-168 for MLN2238
type
SECONDARY
unit Of Measure
unitless

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice